ImmunityBio, Inc. IBRX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ImmunityBio, Inc. reported revenue across 1 business segments; the largest, Reportable Segment, was $113M, 100.0% of the filed sum (+668.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$113M100.0%+668.3% yoy
Members sum to the consolidated $113M for this period.
- Reportable Segment-$256M100.0%-25.6% yoy
Members sum to the consolidated -$256M for this period.
- Product$113M99.7%+698.5% yoy
- Product And Service Other$306K0.3%-48.6% yoy
Members sum to the consolidated $113M for this period.
- United States$113M99.8%+695.1% yoy
- Europe$278K0.2%-47.6% yoy
Members sum to the consolidated $113M for this period.
- Reportable Segment$44.2M100.0%+167.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.